MK-3475 and BCG
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma
Conditions
High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells
Trial Timeline
Nov 30, 2017 → Jan 1, 2021
NCT ID
NCT03345134About MK-3475 and BCG
MK-3475 and BCG is a phase 2 stage product being developed by Merck for High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03345134. Target conditions include High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma, Endoscopic Surgical Procedure, Transitional Epithelial Cells.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03345134 | Phase 2 | Recruiting |
Competing Products
20 competing products in High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma